title: In vitro characterization of the effects of MCI-154, a novel cardiotonic agent, on cardiac tissues.
abstract: In vitro cardiac effects of a cardiotonic drug, MCI-154, for which the main action mechanism was proposed to be the enhancement of Ca2+ sensitivity of cardiac contractile proteins, were investigated. MCI-154 (3 x 10(-8)-3 x 10(-4) M) increased the developed tension in isolated ventricular muscles from cats, dogs, guinea pigs and rats and increased that of isolated left atrial muscles of guinea pigs and rats. However, species differences were observed in the responses to MCI-154. The positive inotropic potency of MCI-154 was stronger than those of amrinone and milrinone. In the isolated right atria from guinea pigs and rats, properties of the chronotropic effect of MCI-154 were different from those of amrinone and milrinone. The positive inotropic action of MCI-154 was not affected by phentolamine, propranolol, cimetidine and tetrodotoxin. MCI-154 did not inhibit cardiac Na+,K+-ATPase. MCI-154 moderately stimulated Ca2+-uptake of isolated cardiac sarcoplasmic reticulum (SR), but induced no release of Ca2+ from the SR. These results support the view that the main mechanism for the action of MCI-154 is the enhancement of Ca2+ sensitivity of cardiac contractile proteins.
authors.affiliation: Pharmaceuticals Laboratory, Mitsubishi Kasei Corporation, Yokohama, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Narimatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Kitada
authors.forename: N
authors.initials: N
authors.lastname: Satoh
authors.forename: M
authors.initials: M
authors.lastname: Morita
authors.forename: A
authors.initials: A
authors.lastname: Muroyama
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Ohizumi
mesh_terms: D000676:Amrinone / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D002316:Cardiotonic Agents / Q000494:pharmacology*; D002415:Cats; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D020105:Milrinone; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000201:enzymology; D011724:Pyridazines / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D011724:Pyridazines; D011728:Pyridones; C052228:MCI 154; D000252:Calcium-Transporting ATPases; D000254:Sodium-Potassium-Exchanging ATPase; D020105:Milrinone; D000676:Amrinone; D002118:Calcium